ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologics"

  • Abstract Number: 1504 • 2019 ACR/ARP Annual Meeting

    Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years

    Helena Marzo-Ortega1, Corinne Miceli-Richard 2, Sonja Gill 3, Marina Magrey 4, Paula Machado 5, Abhijit Shete 6, Jianyuan Wang 6, Susanne Rohrer 6 and Atul Deodhar 7, 1NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom, 2Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, 3412 – 3075 Hospital Gate, Oakville, Canada, 4Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, 6Novartis Pharma AG, Basel, Switzerland, 7Oregon Health & Science University, Portland, OR

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory condition. Pain, stiffness, and fatigue are reported as the most troubling symptoms by 70–80%, 20–40%, and 50–60%…
  • Abstract Number: 2399 • 2019 ACR/ARP Annual Meeting

    Changes in the Initial Usage Pattern of Biologic Disease-modifying Antirheumatic Drugs in Rheumatic Diseases During the past Twelve Years: A Real-world Setting Analysis

    Carlos Sánchez-Piedra1, María Colazo 2, Rosa Roselló 3, Cristina Campos 4, P. Vela 5, Cristina Bohorquez 6, Carolina Pérez-García 7, Manuel Pombo-Suarez 8, Carlos Fernández-López 9, Dolores Ruiz-Montesinos 10, Fernando Alonso 11, Federico Diaz-Gonzalez 12 and Juan Jesús Gómez-Reino 13, 1Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 2Hospital de Burgos, Burgos, 3Hospital San Jorge, Huesca, 4Hospital General de Valencia, Valencia, 5Hospital General Universitario de Alicante, Alicante, Comunidad Valenciana, Spain, 6Universitary Hospital Príncipe de Asturias, Immune System Diseases, Rheumatology department, Alcala de Henares, Spain, 7Rheumatology, Hospital del Mar, Barcelona, Catalonia, Spain, 8Unit Research, Spanish Society of Rheumatology, Madrid, Spain, 9Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, 10Hospital Virgen Macarena, Sevilla, 11Unidad Investigación SER, Madrid, Spain, 12Hospital de Canarias, Tenerife, 13Hospital de Santiago, Santiago de Compostela

    Background/Purpose: During the past 15 years, advancements in the understanding of the safety and effectiveness, as well as the expanding access and availability of biologic…
  • Abstract Number: 1515 • 2019 ACR/ARP Annual Meeting

    Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials

    Marina Magrey1, Victoria Navarro-Compán 2, Sandra Garces 3, Xenofon Baraliakos 4, David Sandoval 3, Jeffrey Lisse 3, Silvia Santisteban 3, David Adams 3, Fangyi Zhao 3 and Robert Inman 5, 1Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, 2University Hospital La Paz, IdiPaz, Madrid, Spain, 3Eli Lilly and Company, Indianapolis, IN, 4Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, 5University of Toronto, University Health Network, Toronto, ON, Canada

    Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A. IL-17 inhibitors have shown efficacy for radiographic axial spondyloarthritis (r-axSpA), with IXE currently…
  • Abstract Number: 2505 • 2019 ACR/ARP Annual Meeting

    Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina

    Luciano Fernando Lo Giudice1, Maria Laura Acosta Felquer 1, Luis Daniel Mazzuoccolo 2, Maria Laura Galimberti 2 and Enrique Soriano 3, 1Hospital Italiano de Buenos Aires, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 2Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 3Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: As psoriasis (Pso) commonly precedes psoriatic arthritis (PsA), an important unanswered question is whether treatment of Pso might influence the development of PsA in…
  • Abstract Number: 1520 • 2019 ACR/ARP Annual Meeting

    Long-Term Treatment Patterns of Biologics and Apremilast Among Patients with Moderate-to-Severe Plaque Psoriasis by Psoriatic Arthritis Status

    Steven Feldman 1, Jingchuan Zhang2, Diane Martinez 3, Lorena Lopez-Gonzalez 3, Elizabeth Holt Marchlewicz 3, George Shrady 3, Alan Mendelsohn 4 and Yang zhao 5, 1Wake Forest Baptist Health, Winston-Salem, NC, 2Sun Pharmaceutical Industries, Princeton, NJ, 3IBM Watson Health, Washington, DC, 4Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, 5Sun Pharmaceutical Industries, Princeton

    Background/Purpose: Long-term real-world treatment patterns of psoriasis patients are not well characterized, especially those with comorbid psoriatic arthritis (PsA). This study examined the treatment patterns…
  • Abstract Number: 2544 • 2019 ACR/ARP Annual Meeting

    Results of the Open-label, Non-randomized 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment with Belimumab in Patients with SLE

    Sang-Cheol Bae1, Richard Dimelow 2, Beulah Ji 3, Regina Kurrasch 4, Saima Muzaffar 5, Raj Punwaney 4, David Roth 4, Paul Stober 4, Yeong-Wook Song 6, Wendy Xie 4 and Fengchun Zhang 7, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 2GSK, Stevenage, United Kingdom, 3GSK, Uxbridge, Middlesex, United Kingdom, 4GSK, Collegeville, PA, 5GSK, Stevenage, Hertfordshire, 6Seoul National University Hospital, Seoul, Republic of Korea, 7Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (People's Republic)

    Background/Purpose: Belimumab is approved as add-on therapy in active, autoantibody-positive SLE. Safety and efficacy up to 13 years has been reported in adults, but potential…
  • Abstract Number: 71 • 2019 ACR/ARP Annual Meeting

    Inhibition of Nuclear Pore Export Ameliorates Lupus via Modulation of Plasma Cell Generation and Survival

    Javier Rangel-Moreno1, Maria de la luz Garcia-Hernandez 2, Teresa Owen 3, Jennifer Barnard 3, Bruce Goldman 3, Christopher Ritchlin 2, Douglas Widman 4, Savanna Gornisiewicz 4, Sharon Tamir 4 and Jennifer H Anolik 3, 1University of Rochester Medical center, Rochester, NY, 2Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, 3University of Rochester, Rochester, NY, 4Karyopharm Therapeutics, Newton, MA

    Background/Purpose: A major challenge in lupus is the elimination of autoreactive plasma cells, which amplify inflammation at peripheral sites via deposition of autoantibody-self antigen complexes.…
  • Abstract Number: 1522 • 2019 ACR/ARP Annual Meeting

    Inflammatory Bowel Disease and Anterior Uveitis in Patients Treated with Ixekizumab for Radiographic Axial Spondyloarthritis: Results from Two Phase 3 Studies Through 52 Weeks

    Sergio Schwartzman1, Atul Deodhar 2, Andris Kronbergs 3, Silvia Santisteban 3, Sandra Garces 3, David Sandoval 3, Jeffrey Lisse 3, Fangyi Zhao 3, Denis Poddubnyy 4 and James Rosenbaum 5, 1The Hospital for Special Surgery, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY, 2Oregon Health & Science University, Portland, OR, 3Eli Lilly and Company, Indianapolis, IN, 4Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, 5Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health and Science University, Portland, OR

    Background/Purpose: Radiographic axial spondyloarthritis (r-axSpA) is a chronic inflammatory disease involving the axial skeleton; inflammatory bowel disease (IBD) and acute anterior uveitis (AAU) are common…
  • Abstract Number: 2665 • 2019 ACR/ARP Annual Meeting

    Clinical Outcomes of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica Symptoms Treated with Tocilizumab in Routine Clinical Practice

    Sebastian Unizony1, Robert Spiera 2, Jinglan Pei 3, Páris Sidiropoulos 3, Jennie Best 4 and John Stone 1, 1Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 2Hospital for Special Surgery, New York, NY, 3Genentech, South San Francisco, CA, 4Genentech, Inc., South San Francisco, CA

    Background/Purpose: Approximately 50% of patients with giant cell arteritis (GCA) also have polymyalgia rheumatica (PMR) symptoms.1 The purpose of this study was to determine whether…
  • Abstract Number: 194 • 2019 ACR/ARP Annual Meeting

    Predicting Remission in Rheumatoid Arthritis: External Validation for Tocilizumab Monotherapy Using Corrona Real World Data

    Fredrik Johansson1, Jamie Collins 2, Sara Gale 3, Hongshu Guan 4, Seoyoung C. Kim 5, Elena Losina 6, David Sontag 1, Jacklyn Stratton 4, Huong Trinh 3, Jeffrey Greenberg 7 and Daniel Solomon 8, 1MIT, Cambridge, MA, 2Brigham and Women's Hospital and Harvard Medical School, Boston, 3Genentech, San Francisco, CA, 4Brigham and Women's Hospital, Boston, 5Brigham and Women’s Hospital and Harvard Medical School, Boston, 6Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 7Corrona, LLC; NYU School of Medicine, Waltham, MA, 8Brigham and Women´s Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA

    Background/Purpose: Predicting remission in rheumatoid arthritis (RA) is an important goal for tailoring therapy. Tocilizumab (TCZ) has been found in randomized controlled trials (RCT) to…
  • Abstract Number: 1554 • 2019 ACR/ARP Annual Meeting

    Effect of Secukinumab on Radiographic Progression Through 2 Years in Patients with Active Psoriatic Arthritis: End-of-study Results from a Phase III Study

    Philip Mease1, Robert B.M. Landewé 2, Proton Rahman 3, Hasan Tahir 4, Atul Singhal 5, Elke Böttcher 6, Sandra Navarra 7, Aimee Readie 8, Shephard Mpofu 9, Evie Maria Delicha 9, Luminita Pricop 8 and Désirée van der Heijde 10, 1Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, 2Amsterdam University Medical Center, Amsterdam, Netherlands, 3Memorial University, Newfoundland, NL, Canada, 4Department of Rheumatology, Whipps Cross University Hospital, London, United Kingdom, 5Southwest Rheumatology, Dallas, TX, 6Rheumazentrum Favoriten, Vienna, Austria, 7University of Santo Tomas Hospital, Manila, Philippines, 8Novartis Pharmaceuticals Corporation, East Hanover, NJ, 9Novartis Pharma AG, Basel, Switzerland, 10Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Secukinumab (SEC) provided sustained efficacy, inhibition of radiographic progression, and stable safety profile over 52 Weeks (Wks) in patients (pts) with psoriatic arthritis (PsA)…
  • Abstract Number: 2694 • 2019 ACR/ARP Annual Meeting

    Inpatient Treatment Variation in New-Onset Systemic Juvenile Idiopathic Arthritis

    Rosemary Peterson1, Rui Xiao 2, Hannah Katcoff 1, Brian Fisher 1 and Pamela F. Weiss 1, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia

    Background/Purpose: The effectiveness of IL-1 and IL-6 inhibitors as first-line therapy in patients with new-onset systemic JIA has led to the concept of a “window…
  • Abstract Number: 217 • 2019 ACR/ARP Annual Meeting

    Fibromyalgia and Multiple Switching of Biologics in Spondylarthritis

    Ahmed Negm1, Nasir Elsidig 1, Ahlam Al Marzooqi 1, Noura Zamani 1, Ayesha Hossaini 1 and Jamal Al Saleh 1, 1Rheumatology Department, Dubai Hospital- Dubai Health Authority, Dubai, Dubai, United Arab Emirates

    Background/Purpose: Fibromyalgia (FM) is a condition characterized by chronic widespread pain, tender points, fatigue and disturbed sleep rhythm. Some of these symptoms such as fatigue,…
  • Abstract Number: 1812 • 2019 ACR/ARP Annual Meeting

    Delineating Early Response Trajectories to Biologics in Polyarticular Course Juvenile Idiopathic Arthritis

    Lily SH Lim1, Armend Lokku 2, Sarah Ringold 3 and Eleanor M. Pullenayegum 4, 1University of Manitoba, Winnipeg, MB, Canada, 2University of Toronto, TOronto, ON, Canada, 3Seattle Children's, Seattle, 4Child Health Evaluative Sciences, The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

    Background/Purpose: Most biologic trials in juvenile idiopathic arthritis (JIA) treat all participants with the biologic under study for 12 to 16 weeks before randomizing responders…
  • Abstract Number: 2707 • 2019 ACR/ARP Annual Meeting

    Improvement in Patient-Reported Outcomes in Patients Aged 2–5 Years with Polyarticular-Course JIA Treated with Subcutaneous Abatacept: 2-Year Results from a Phase III International Study

    Hermine Brunner1, Nikolay Tzaribachev 2, Ingrid Louw 3, Jordi Antón 4, Diego Viola 5, Bernard Lauwerys 6, Rubèn J Cuttica 7, Pierre Quartier 8, Elisabeth Gervais 9, Alexandre Belot 10, Kirsten Minden 11, Thomas Lutz 12, Rolando Cimaz 13, Mahmood M. T. M. Ally 14, Riana van Zyl 15, Inmaculada Calvo Penadés 16, Joe Zhuo 17, Robert Wong 18, Marleen Nys 19, Yedid Elbez 20, Alberto Martini 21, Daniel J. Lovell 22 and Nicolino Ruperto 23, 1Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, 3Panorama Medical Centre, Parow, South Africa, 4Hospital Sant Joan de Déu, Barcelona, Spain, 5CAICI Institute, Rosario City, Santa Fe State, Argentina, 6Rheumatology, Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, Brussels, Belgium, 7Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, 8Necker Hospital, Paris, France, 9CHU de Poitiers, Rheumatology, Poitiers, France, 10Centre Hospitalier Universitaire de Lyon, Lyon, France, 11German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, 12Heidelberg University Hospital, Heidelberg, Germany, 13Meyer Children's Hospital in Florence, Florence, Italy, 14University of Pretoria, Pretoria, South Africa, 15University of the Free State, Bloemfontein, South Africa, 16Hospital Univ. La Fe, Valencia, Spain, 17Bristol-Myers Squibb, Princeton, NJ, 18Bristol-Myers Squibb, Princeton, 19Bristol-Myers Squibb, Braine L’Alleud, Belgium, 20Excelya, Boulogne-Billancourt, France, 21IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, 22Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, 23Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy

    Background/Purpose: Efficacy of SC abatacept in patients with polyarticular-course JIA (pJIA) was shown in a 2-year, open-label, Phase III international study (NCT01844518).1 Pediatric patient-reported outcomes…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology